ProMIS Neurosciences Inc. (T:PMN*CA)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: Suite 200, 1920 Yonge Street
TORONTO ON M4S 3E2
Tel: N/A
Website: https://www.promisneurosciences.com
IR: See website
<
Key People
Eugene Williams
Executive Chairman of the Board
Gail M. Farfel
Chief Executive Officer, Director
Neil Cashman
Co-Founder, Chief Scientific Officer, Director
Daniel E. Geffken
Chief Financial Officer
Gavin Malenfant
Chief Operating Officer
Larry Altstiel
Chief Medical Officer
Johanne Kaplan
Chief Development Officer
David Wishart
Chief Physics Officer
 
Business Overview
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.
Financial Overview
For the nine months ended 30 September 2023, Promis Neurosciences Inc revenues was not reported. Net loss decreased 11% to $9.6M. Lower net loss reflects Research and development - Balancing val decrease of 51% to $4.5M (expense), General and administrative - Balancing v decrease of 17% to $3.9M (expense), Other interest expense decrease from $282K (expense) to $0K.
Employees: 6 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $16.15M as of Sep 30, 2023
Annual revenue (TTM): $0.00M as of Sep 30, 2023
EBITDA (TTM): -$18.91M as of Sep 30, 2023
Net annual income (TTM): -$16.90M as of Sep 30, 2023
Free cash flow (TTM): -$11.64M as of Sep 30, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 18,885,254 as of Nov 10, 2023
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.